Reconsidering Adjuvant Immunotherapy for Tuberculosis
The DOI matches its Crossref record; 75 of the 75 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Shortened regimens for treatment of pulmonary tuberculosis (TB) are urgently needed to facilitate its global eradication. Prolonged treatment is presently required to prevent relapse, which is thought to arise from persisting foci of semidormant infection contained within granulomas. METHODS: The medical literature was reviewed to identify clinical trials of adjuvant TB immunotherapy, as well as other studies of the relationship between immune status and TB relapse or reactivation. RESULTS: Four studies of therapeutic interferon indicated its inability to effectively augment the mycobactericidal capacity of lung macrophages. One randomized, placebo-controlled trial of therapeutic interleukin-2 found that it delayed the microbiologic response to treatment, whereas 2 controlled trials of anti-tumor necrosis factor (TNF) therapies (high-dose prednisolone and etanercept [a soluble TNF receptor]) found that these interventions significantly accelerated the response to treatment. Four retrospective studies were identified in which the response to TB therapy was accelerated and/or the relapse risk was reduced in persons with human immunodeficiency virus coinfection; one study reported that immune reconstitution syndrome due to use of antiretroviral therapy was associated with increased risk of relapse. Several studies indicated that granulomas may be efficiently targeted and disrupted by the anti-TNF antibody infliximab, apparently because of its ability to bind to cell-surface TNF and to induce apoptosis in TNF-expressing cells. CONCLUSIONS: These findings support the hypothesis that the granulomatous host response to TB may paradoxically protect sequestered mycobacteria from administered anti-TB therapy and that treatment may be improved by therapeutic disruption of granulomas. Clinical trials to test this hypothesis are warranted.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
Tuberculosis Associated with Infliximab, a Tumor Necrosis Factor α–Neutralizing Agent
Keane, J., Gershon, S., Wise, R. P., Mirabile-Levens, E., Kasznica, J., Schwieterman, W. D., Siegel, J. N., & Braun, M. M. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011110 · Cited by 3,710
A metalloproteinase disintegrin that releases tumour-necrosis factor-α from cells
Black, R. A., Rauch, C. T., Kozlosky, C. J., Peschon, J. J., Slack, J. L., Wolfson, M. F., Castner, B. J., Stocking, K. L., Reddy, P., Srinivasan, S., et al. (1997) · Nature · doi:10.1038/385729a0 · Cited by 3,149 · cited 1×
“ing domains, as a soluble homotrimer [26, 27].”
Flynn, J. L., Goldstein, M. M., Chan, J., Triebold, K. J., Pfeffer, K., Lowenstein, C. J., Schrelber, R., Mak, T. W., & Bloom, B. R. (1995) · Immunity · doi:10.1016/1074-7613(95)90001-2 · Cited by 1,677 · cited 1×
“As a result, animals deficient in TNF are highly susceptible to granulomatous infections [41].”
BackgroundMcKinney, J. D., zu Bentrup, K. H., Muñoz-Elías, E. J., Miczak, A., Chen, B., Chan, W.-T., Swenson, D., Sacchettini, J. C., Jacobs, W. R., & Russell, D. G. (2000) · Nature · doi:10.1038/35021074 · Cited by 1,360 · cited 1×
“oxygen deprivation or intracellular growth in macrophages [ 1-9].”
BackgroundKindler, V., Sappino, A.-P., Grau, G. E., Piguet, P.-F., & Vassalli, P. (1989) · Cell · doi:10.1016/0092-8674(89)90676-4 · Cited by 1,254 · cited 1×
“tuberculosis infection and inhibits the orderly formation of granulomas [37, 38].”
BackgroundChan, J., Xing, Y., Magliozzo, R. S., & Bloom, B. R. (1992) · The Journal of experimental medicine · doi:10.1084/jem.175.4.1111 · Cited by 1,062 · cited 1×
“production of reactive nitrogen intermediates, such as nitric oxide [16, 17].”
BackgroundGranulomatous Infectious Diseases Associated with Tumor Necrosis Factor Antagonists
Wallis, R. S., Broder, M. S., Wong, J. Y., Hanson, M. E., & Beenhouwer, D. O. (2004) · Clinical Infectious Diseases · doi:10.1086/383317 · Cited by 977
Self-citationInhibition of Respiration by Nitric Oxide Induces a Mycobacterium tuberculosis Dormancy Program
Voskuil, M. I., Schnappinger, D., Visconti, K. C., Harrell, M. I., Dolganov, G. M., Sherman, D. R., & Schoolnik, G. K. (2003) · The Journal of Experimental Medicine · doi:10.1084/jem.20030205 · Cited by 966 · cited 1×
“oxygen deprivation or intracellular growth in macrophages [ 1-9].”
BackgroundEtanercept for active Crohn's disease: A randomized, double-blind, placebo-controlled trial
Sandborn, W. J., Hanauer, S. B., Katz, S., Safdi, M., Wolf, D. G., Baerg, R. D., Tremaine, W. J., Johnson, T., Diehl, N. N., & Zinsmeister, A. R. (2001) · Gastroenterology · doi:10.1053/gast.2001.28674 · Cited by 910 · cited 1×
“Crohn disease, sarcoidosis, or Wegener granulomatosis [68-71].”
Interferon-γ –Receptor Deficiency in an Infant with Fatal Bacille Calmette–Guérin Infection
Jouanguy, E., Altare, F., Lamhamedi, S., Revy, P., Emile, J.-F., Newport, M., Levin, M., Blanche, S., Seboun, E., Fischer, A., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199612263352604 · Cited by 895
Research works printed but not linked: 10
- O’Brien RJ, 2001, Global Alliance for TB Drug Development. Tuberculosis, 81, 1
- Giosue S, 2000, Eur Cytokine Netw, 11, 99
- InterMune investor relations press release: InterMune enrolls first patient in phase III trial in multidrug-resistant tuberculosis. 2000. Available at: http://www.hopkins-tb.org/news/7-31-2000.shtml. Accessed 18 May 2005.
- de Oliveira MM, 2004, Jornal Brasileiro Pneumologia, 30, 461
- East African-British Medical Research Councils, 1974, Lancet, 2, 237
- Bilaceroglu S, 1999, Int J Tuberc Lung Dis, 3, 47
- Dhillon J, 1989, Br J Exp Pathol, 70, 103
- Batten JC, 1957, Br J Exp Pathol, 38, 424
- Flynn JL, 2004, Tuberculosis. Philadelphia: Lippincott Williams & Wilkins, 237
- Joloba ML, 2000, Int J Tuberc Lung Dis, 4, 528
Cited by
Items 101–121 of 121
Fulminant Pulmonary Tuberculosis by Infliximab in Patient with Rheumatoid Arthritis
Hama, M., & Yamazaki, Y. (2016) · Mycobacterial Diseases · doi:10.4172/2161-1068.1000206 · Cited by 1
l-Arginine in Pulmonary Tuberculosis
Ralph, A. P. (2016) · Springer eBooks · doi:10.1007/978-3-319-26009-9_47 · Cited by 1
Clinical Analysis of Miliary Tuberculosis Patients in Our Tertiary Hospital
Kobashi, Y., Kittaka, M., Mouri, K., Kato, S., & Oka, M. (2017) · Journal of Tuberculosis Research · doi:10.4236/jtr.2017.51010 · Cited by 1
“Although there are a few reports suggesting that the administration of corticosteroid drugs is effective for the treatment of ARDS complicated with miliary TB [15] [16] [17], they were not effective for case 6 in this study.”
BackgroundQuintas, S., Sánchez, P., López, M., & Vivancos, J. (2019) · Journal of Clinical Neuroscience · doi:10.1016/j.jocn.2018.12.018 · Cited by 1
Higashiguchi, M., Matsumoto, T., Nishioka, K., Kimura, H., Kuwahara, M., & Komuta, K. (2023) · Journal of Infection and Chemotherapy · doi:10.1016/j.jiac.2023.05.018 · Cited by 1
Sakr, M. F. (2024) · Springer eBooks · doi:10.1007/978-3-031-64102-2_10 · Cited by 1
Extensively Drug-Resistant Tuberculosis
Schluger, N. W. (2014) · ASM Press eBooks · doi:10.1128/9781555815592.ch17 · Cited by 1
Therapy for Tuberculosis: M. vaccae Inclusion into Routine Treatment
Diana, G., Stanford, C. A., & Stanfor, J. (2012) · InTech eBooks · doi:10.5772/31811
Nontuberculous Mycobacterium Infections in Rheumatoid Arthritis Patients
Watanabe, M., & Banno, S. (2012) · InTech eBooks · doi:10.5772/27169
Immunothérapie de la tuberculose
HOUSSET, B., & Postel‐Vinay, N. (2006) · Revue des Maladies Respiratoires · doi:10.1016/s0761-8425(06)77728-2
Elucidation of the aerobic respiratory chains in mycobacteria
Matsoso, L. G. (2006) · University of the Witwatersrand, Johannesburg Institutional Repository on DSpace (University of the Witwatersrand, Johannesburg)
Alternative Mutational Pathways to Increased Vancomycin Resistance in MRSA
Seligman, S. J. (2013) · The Journal of Infectious Diseases · doi:10.1093/infdis/jit516
Kıyıcı, M., Özal, G., Dolar, E., Gülten, M., Nak, S. G., Gürel, E., Uslusoy, H. S., & Keskın, M. (2006) · DergiPark (Istanbul University)
EDITORIAL Manifestation of Mycobacterium infection other than Tuberculosis
Gupta, D., Sarin, R., Singla, N., Behera, D., Khan, S., James, P., Gupta, R., Thangakunam, B., Dixit, R., Arya, M. K., et al. (2010)
New therapeutics in development and future directions
Upton, A. M., & Ma, Z. (2011) · doi:10.2217/ebo.11.36
Faïz, S., Ettahar, N., Sabbah, M., Toné, A., Benrezkallah, M., Bourgarit, A., & Chopin, M. (2018) · Médecine et Maladies Infectieuses · doi:10.1016/j.medmal.2018.06.001
Aldrich, C. C., Wallis, R. S., Remmel, R. P., Hegde, P. V., & Stallings, C. L. (2021) · Wiley eBooks · doi:10.1002/0471266949.bmc298
Self-citationCystic Swellings of the Anterior Triangle: Cervical Abscesses
Sakr, M. F. (2023) · Springer eBooks · doi:10.1007/978-3-031-32118-4_10
Wallis, R. S. (2025) · Elsevier eBooks · doi:10.1016/b978-0-12-824465-4.00163-0
Self-citationSelwyn Selva Kumar, D., Somarkutty, D. N., Jayavelu Hariram Prasad, D., Gautam, P., Veerasamy, N., Rajiv Karthik, K., Vanjare, H. A., Appaswamy, P. T., Michael, J. S., Varghese, G. M., et al. (2025) · Clinical Infectious Diseases · doi:10.1093/cid/ciaf573 · Cited by 1
Lin, F., Tang, X., 费贤树, & Guo, J. (2026) · BMC Infectious Diseases · doi:10.1186/s12879-026-13464-7
“…susceptibility to secondary bacterial/ fungal infections, potential exacerbation of dissemination (e.g., progression of cryptic miliary TB to overt ARDS), delayed mycobacterial clearance, and immuno-suppression-related complications such as opportunistic infections or hyperglycemia [2, 21].”
Metadata
- Authors
- Wallis, R. S.
- Affiliations
- Pharmaceutical Product Development (United States) (US)
- Corresponding author
- Wallis, Robert S.
- ORCID
- Wallis, Robert S.
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2005-07-15
- Volume
- 41
- Issue
- 2
- Pages
- 201-208
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- OpenAlex
- W2133199321
- Cited by
- 121
- References
- 75
- Citations by year
- 2026: 1 · 2025: 3 · 2024: 2 · 2023: 6 · 2022: 2 · 2021: 2 · 2020: 1 · 2019: 3 · 2018: 5 · 2017: 2 · 2016: 7 · 2015: 5 · 2014: 7 · 2013: 5 · 2012: 13
- FWCI
- 1.29
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Clinical Infectious Diseases (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Amgen
- Louisiana State University
- Topics
- Health Sciences › Medicine › Infectious Diseases › Tuberculosis Research and Epidemiology
- Health Sciences › Medicine › Infectious Diseases › Infectious Diseases and Tuberculosis
- Life Sciences › Immunology and Microbiology › Immunology › Immune responses and vaccinations
- Keywords
- pulmonary tuberculosis, adjuvant immunotherapy, tuberculosis relapse, granuloma, anti-TNF therapy, infliximab, etanercept, prednisolone, interleukin-2, interferon therapy, HIV coinfection, immune reconstitution inflammatory syndrome, antiretroviral therapy, tuberculosis treatment response
- MeSH terms
- Antitubercular Agents, Humans, Immunotherapy, Tuberculosis, Pulmonary, Drug Resistance, Multiple, Bacterial
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.